Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SLXN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSilexion announces 1-for-10 reverse stock split effective May 28, 2026
Filed May 26, 2026 · Period ending May 26, 2026 · ~1 min read
Key Changes
-
high
Every 10 shares will consolidate into 1 share after market close May 28, with adjusted trading starting May 29 on Nasdaq. Reverse splits typically aim to boost share price for exchange compliance or market perception.
Item 8.01 verify on EDGAR → -
medium
Fractional shares will be rounded up to the nearest whole share for DTC participants, meaning shareholders receive additional value rather than cash for fractional interests.
Item 8.01 verify on EDGAR → -
low
Par value increases from $0.0135 to $0.135 per share, a technical adjustment proportional to the 10-to-1 ratio with no direct economic impact on shareholders.
Item 8.01 verify on EDGAR →
Summary
Silexion Therapeutics announced a 1-for-10 reverse stock split taking effect after market close on May 28, 2026. Shareholders will see their share count reduced by 90%, though their proportional ownership and total value remain unchanged. The company's stock will trade on the adjusted basis starting May 29 on Nasdaq.
Reverse splits are often implemented when a company's share price has fallen too low, either to maintain exchange listing requirements or to improve institutional investor perception. For Silexion holders, this means a higher per-share price but fewer shares. Importantly, any fractional shares will be rounded up rather than cashed out, a shareholder-friendly provision. Retail investors should monitor whether the split successfully stabilizes the stock price above key thresholds and watch for any subsequent dilution through new share issuances, which can quickly erode the benefits of a reverse split.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
on May 26, 2026, Silexion Therapeutics Corp, a Cayman Islands exempted company (“Silexion” or the “Company”) issued a press release announcing a prospective 1-for-10 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares. The reverse share split will become effective after the close of the market on May 28, 2026, and the Company’s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at the open of the market on May 29, 2026.
The Company is implementing a 1-for-10 reverse stock split, meaning every 10 shares will be consolidated into 1 share. This becomes effective after market close on May 28, 2026, with trading on the adjusted basis starting May 29, 2026. Reverse splits are often used to increase share price to meet exchange listing requirements or improve market perception.
Event · Item 9.01 — Financial Statements and Exhibits
Silexion Therapeutics filed an 8-K attaching a press release dated May 26, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1 Press Release dated May 26, 2026
The 8-K references an attached press release dated May 26, 2026 under Exhibit 99.1. The filing body itself does not disclose the content or subject matter of the press release, so the materiality and investor relevance cannot be determined from this 8-K text alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify